BioHarvest Sciences, the Consumer Defensive sector company, was revisited by a Wall Street analyst today. Analyst Amit Dayal from H.C. Wainwright maintained a Buy rating on the stock and has a $14.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amit Dayal has given his Buy rating due to a combination of factors tied to BioHarvest Sciences’ growth outlook and improving fundamentals. He highlights management’s 2026 guidance, which calls for meaningful revenue expansion, improving gross margins supported by better manufacturing efficiency and a richer product mix, and growing CDMO contributions despite seasonal softness in early quarters.
He also emphasizes the strong momentum of the VINIA brand in the U.S. and the company’s plan to extend it into higher-value health categories, as well as the long-term upside from CDMO partnerships enhanced by AI-driven molecule discovery. His financial model anticipates sustained double-digit revenue growth, expanding profitability with positive adjusted EBITDA from 2027 onward, and a DCF-derived value per share that supports a $14 price target even after factoring in execution risk and broader operational uncertainties.